1. The contradiction, in one chart

The companion piece on PLI-MD's coverage lists endoscopes among ten device categories the scheme never addressed: $112mn in imports for FY2025-26 (provisional), Japan-dominated supply, no PLI applicant in the space beyond an adjacent urology-niche Cat-B entrant. Read in isolation, that sounds like every other name on that list — pacemakers, ophthalmic instruments, dental, hearing aids — all import-dependent, all unaddressed. But the same TradeStat fetch that produced the $112mn figure also reports endoscopes running 57% export coverage: India exports roughly $64mn against that $112mn of imports. That beats every PLI-covered category in the trade-gap piece's dataset except dialysis machines (71%, built on Nipro's renal-care manufacturing), and comfortably beats oxygen concentrators (9%, despite four PLI applicants) and pacemakers (1%, nominally inside PLI's implant scope but with zero applicants making one).

2. What's actually inside the $112mn line

Endoscopes sit within the broader “surgical & diagnostic instruments” family that the trade-gap piece tracks separately: $3,097mn in imports, +10.5% YoY, 48% coverage overall. Endoscopes specifically, at 57%, are already outperforming that family average — one of the few HS lines in the entire 148-code device basket where India's exports keep pace with a Japan-dominated import bill rather than trailing it by a wide margin. Globally, flexible-endoscope manufacturing is a concentrated business: Olympus, Fujifilm/Pentax (HOYA) and Karl Storz are consistently named as the market's dominant players across industry research reports, which is the general context for why “Japan-dominated” shows up in the trade data at all. What the TradeStat fetch can't say, at the level of detail available here, is exactly what's inside that 57% export figure — whether it's finished rigid/flexible scopes, sub-assemblies, or re-exported components. That composition question is the one this piece can't close with the data in hand.

3. The applicant next door, not in it

The one PLI-MD name anywhere near this space is Indovasive, the Cat-B urology applicant covering the “full catheter/stent/guidewire/lithotripsy-laser range.” Those are exactly the instruments used alongside an endoscopic urology procedure — a ureteroscopy or cystoscopy needs a guidewire, often a lithotripsy laser, and a stent afterward. What PLI-MD funded there is the consumable and energy-device layer around the procedure, not the ureteroscope or cystoscope itself. That's a real, if narrow, foothold in endoscopic urology's supply chain — and precisely why the companion piece describes endoscopes as having only an adjacent, not a direct, PLI applicant.

4. Why the scheme never named it

PLI-MD's scope was never open-ended: the Department of Pharmaceuticals' official list of 38 high-end devices under the scheme (PIB Press Release ID 2227618, 13 February 2026) simply doesn't include endoscopes as a line item, in the way it does name CT, MRI, dialysers and implants. And per the Department's own statement to Lok Sabha (PIB PRID 2204598, 16 December 2025), PLI-MD closes to new applicants in March 2027 with a one-year gestation period — so there is no route left to add endoscopes to that particular list even if a strong applicant turned up tomorrow.

5. Where a future applicant would actually go

The live door is SMDI (Scheme for Strengthening of Medical Device Industry), whose components/accessories window has been open since June 2026. Unlike PLI-MD's closed, fixed 38-device list, SMDI's Marginal Investment Scheme is built around reducing import dependence for components, raw materials, finished devices and accessories generally — it is not restricted to a named device roster the way PLI-MD was. That structural difference matters here specifically: an endoscope-optics or endoscope-shaft manufacturer that could never have qualified for PLI-MD (wrong list) is exactly the kind of applicant SMDI's design is meant to catch. The National Medical Devices Policy 2023's 10–12% global-share target by 2047, and the four Medical Device Parks (Himachal Pradesh, Madhya Pradesh, Tamil Nadu, Uttar Pradesh), are the other pieces of scaffolding already in place if that applicant appears.

6. The demand side keeps climbing — and the product category is splitting in three

None of this is a shrinking market. Gastrointestinal and urological endoscopy volumes rise with age-related disease burden and earlier cancer screening, and the “rigid/ flexible endoscope” line the trade data tracks is no longer the whole category. At least three newer technology tracks are growing alongside the conventional scope, each with its own supply chain — and none of them shows up as a separate line in Indian trade or PLI data yet:

• Capsule endoscopy (PillCam, now Medtronic — originally Given Imaging) — a swallowed, single-use capsule carrying a camera, light source and radio transmitter, first cleared by the US FDA in 2001, with newer generations (PillCam SB3) cleared for at-home ingestion rather than an in-clinic procedure. It solves a real gap: the small intestine sits beyond the reach of both upper endoscopy and colonoscopy, which is why capsule endoscopy has become standard practice for obscure GI bleeding and small-bowel Crohn's disease. This piece could not find a distinct HSN classification, NPPA pricing determination, or PLI/SMDI applicant record specific to capsule endoscopy, as opposed to endoscopes generally.
• Single-use (disposable) endoscopes — a full scope, not just the capsule format, designed to be used once and discarded rather than reprocessed. The push here is infection control: reusable duodenoscopes and bronchoscopes have been linked to hospital-acquired infection outbreaks from incomplete sterilisation, which is why regulators including the US FDA have specifically flagged those two scope types for single-use alternatives. Ambu, Boston Scientific and Olympus are the named players building out this segment globally. A disposable scope is, by construction, a recurring import or a new manufacturing line — it cannot be the same durable, decades-old asset the 57% coverage figure above was presumably built on.
• AI-assisted detection (CADe) systems — software modules such as Medtronic's GI Genius, Olympus's ENDO-AID and Fujifilm's CAD EYE that plug into an existing endoscope's video feed and flag polyps in real time during colonoscopy. These ride on top of conventional hardware rather than replacing it, but they are a growing share of what a modern endoscopy unit actually buys, and they are entirely outside any device-import classification this piece could locate.

None of these three has a confirmed HSN line, NPPA pricing record, or PLI/SMDI applicant trail specific to it in the sources checked for this piece — which is worth flagging rather than papering over. It means the $112mn “endoscopes (rigid/flexible)” figure this piece opened with is almost certainly an undercount of India's total endoscopic-diagnostics import exposure, not an overcount, once capsule devices, disposable scopes and AI-detection modules are counted in. Whether that adds up to another $10mn or another $100mn is not something the TradeStat/PLI sources used here can answer.

7. Bottom line

Endoscopes are the one device family on PLI-MD's own list of gaps that the trade data says India is already handling reasonably well — better, on export coverage, than most of what the scheme actually subsidised. That's a useful corrective to reading the “not addressed by PLI” list as a simple ranking of trouble spots: absence of a PLI applicant correlates only loosely with import dependence once you check the trade numbers line by line. The real gap here isn't the finished scope so much as everything upstream of it — optics, imaging chips, the fibre-optic or video core — and SMDI's open, non-listed components window is the more structurally appropriate vehicle for that than PLI-MD ever was. See the PLI coverage piece for the full gap list this builds on, and the trade-scenario piece for the family-by-family import/export picture.

Sources. FY2025-26 (provisional) TradeStat fetch, 5 August 2026, and Department of Pharmaceuticals PLI-MD approved-applicant list (revised 25 April 2023), both as reported and cited in the companion posts “PLI for Medical Devices: What's Covered, What Isn't” and “India's Medical-Device Trade Gap” on this blog; PIB Press Release ID 2227618 (13 February 2026, official 38-device PLI-MD list); PIB Press Release ID 2204598 (16 December 2025, Lok Sabha statement on scheme closure); Scheme for Strengthening of Medical Device Industry (SMDI) operational guidelines, Department of Pharmaceuticals, components/accessories window live since June 2026. General industry-structure context (dominant flexible-endoscope manufacturers; capsule-endoscopy mechanism and 2001 FDA clearance; single-use endoscope market drivers and named manufacturers; commercial AI computer-aided detection systems) drawn from clinical and industry background sources and presented here as context, not as India-specific trade data.